Status:
UNKNOWN
Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
National Taiwan University Hospital
Conditions:
COPD
Inhaled Corticosteroid
Eligibility:
All Genders
40-99 years
Brief Summary
According to the WISDOM study, withdraw of inhaled steroids has no effect on the acute exacerbation of chronic obstructive pulmonary disease (COPD), but the lung function of patients with COPD is sign...
Eligibility Criteria
Inclusion
- Confirmed patients with COPD (at least one lung function test post bronchodilator FEV1/FVC \<70% before the start of the study)
- Age ≥ 40 years old
- No acute attack record within half a year
- Triple therapy (dual long-acting inhaled bronchodilator and inhaled steroid) is stable for more than six months.
- Eosinophil count in blood \<300 cells/ul
- Clinical symptom assessment CAT score \<20
Exclusion
- Suspected or diagnosed with asthma
- Age \<40 years
- Within half a year, there is a record of moderate to severe acute attacks
- Eosinophil count in blood ≥300 cells/ul
- Clinical symptom assessment CAT score ≥20
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04456205
Start Date
October 1 2019
End Date
October 1 2022
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Yu Chen
Douliu, Yunlin, Taiwan, 640